FDA Warns FITISH Over Compounded GLP-1 Labeling and Ozempic Active-Ingredient Claims
On June 8, 2026, FDA issued a warning letter to FITISH after a March 2026 review of fitish.com, which offers compounded semaglutide and tirzepatide products. FDA says pictured labels identify "FITISH" as if it were the compounder "when in fact it is not," and cites claims including "Semaglutide is the active ingredient in ozempic" and "Tirzepatide is the active ingredient in Mounjaro® and Zepbound®," which FDA says represent unapproved compounded products as FDA-approved. FDA requested a written response within 15 business days.
What this means"Same active ingredient" marketing can blur the line between an FDA-approved drug and a compounded copy that has never been through FDA review — a distinction worth understanding before ordering through any telehealth platform.
Source: FDA original ↗